Fibromyalgia: Laboratory Testing and Management
Laboratory Testing
Fibromyalgia is a clinical diagnosis that does not require extensive laboratory testing; however, baseline labs should be ordered to exclude other conditions that mimic fibromyalgia symptoms. 1, 2
Recommended Baseline Labs:
- Complete blood count (CBC) - to rule out anemia as a cause of fatigue
- Thyroid function tests (TSH) - to exclude thyroid disease presenting with fatigue and pain
- Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) - to rule out inflammatory rheumatic diseases 1, 2
While recent research suggests inflammatory markers (ESR, CRP, neutrophil-lymphocyte ratio, mean platelet volume) may be elevated in fibromyalgia patients 3, these are not diagnostic and should primarily be used to exclude other systemic inflammatory conditions. Do not order extensive imaging or specialized testing unless specific red flags suggest alternative diagnoses 4.
Management Strategy
Exercise is the only therapy with a "strong for" recommendation based on meta-analyses and should be the cornerstone of initial management. 5
Algorithmic Approach (Four-Stage Graduated Model):
Stage 1: Initial Management (All Patients)
- Patient education about fibromyalgia pathophysiology (central sensitization, not tissue damage)
- Graded aerobic exercise program - this is non-negotiable and has the strongest evidence 5, 4
- Shared decision-making with patients about realistic expectations
- Screen for comorbid functional pain syndromes (irritable bowel syndrome, chronic fatigue syndrome, migraine) 1, 2
- Evaluate for mood disorders and anxiety - these are common comorbidities requiring separate treatment 1, 2
Stage 2: Non-Response to Initial Management
Add pharmacotherapy based on dominant symptoms (all medications are "weak for" recommendations based on meta-analyses) 5:
For severe pain and/or sleep disturbance:
- First-line pharmacological options (strongest evidence):
Critical caveat: NSAIDs and opioids have limited proven benefit and should be avoided as primary therapy 4. Opioids should only be used in carefully selected patients after all other therapies fail 1.
Stage 3: Persistent Symptoms Despite Pharmacotherapy
Add psychological therapies specifically targeting:
- Mood disorders (if present)
- Unhelpful coping strategies
- Cognitive-behavioral approaches 5
Stage 4: Severe Disability
Implement multimodal rehabilitation program combining:
- Continued exercise
- Pharmacotherapy
- Psychological interventions
- Functional restoration focus 5
Important Pitfalls to Avoid:
Do not rely on tender point examination - the updated 2010 ACR criteria no longer require this and incorporate widespread pain index and symptom severity scores 1, 4
Do not over-investigate - extensive laboratory testing and imaging delays diagnosis and increases healthcare costs without improving outcomes 5, 4
Do not prescribe opioids as first-line therapy - they have minimal evidence of benefit and significant harm potential 1, 4
Do not treat fibromyalgia as a diagnosis of exclusion - it has distinct pathophysiology involving central amplification of peripheral sensory signals and can coexist with other conditions 1, 6
Tailor pharmacotherapy to individual patient symptoms - the effect size for most medications is modest, and adverse effects are common (e.g., 85% with cyclobenzaprine) 5, 4
Evidence Quality Note:
The 2017 EULAR guidelines 5 represent the highest quality evidence available, based on 107 systematic reviews and meta-analyses. The modest effect sizes across all interventions underscore why exercise remains the only strong recommendation - it has consistent benefit without the adverse effect profile of medications. All pharmacological interventions received only "weak for" recommendations, meaning informed patients might reasonably decline these options 5.